Last reviewed · How we verify
Healthy donor-derived FMT capsule
At a glance
| Generic name | Healthy donor-derived FMT capsule |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Oral Microbiota on MDRO Decolonization (PHASE1, PHASE2)
- Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome (NA)
- Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (PHASE2)
- Aging Resilience Through Microbiota Optimization and Regulation (PHASE1)
- Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation (PHASE1)
- Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease (NA)
- Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV (PHASE1)
- FMT in Children With Autism and Gastrointestinal Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Healthy donor-derived FMT capsule CI brief — competitive landscape report
- Healthy donor-derived FMT capsule updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI